Editorial: Skin Autoimmunity

1 Lübeck Institute of Experimental Dermatology and Center for Research on Inflammation of the Skin, University of Lübeck, Lübeck, Germany, 2 Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel, 3 Department of Dermatology, Allergy, and Venereology and Center for Research on Inflammation of the Skin, University of Lübeck, Lübeck, Germany, 4 Department of Dermatology, Venereology, and Allergology, University Medical Center Göttingen, Göttingen, Germany, 5 Lower Saxony Institute of Occupational Dermatology, University Medical Center Göttingen, Göttingen, Germany, 6 Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi’an, China, 7 Institute of Immunology, University of Oldenburg, Oldenburg, Germany

[1]  H. Nizze,et al.  Impact of diet and genes on murine autoimmune pancreatitis , 2020, Journal of cellular and molecular medicine.

[2]  K. Kähler,et al.  Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[3]  K. Asadullah,et al.  Cytokines of the IL‐17 family in psoriasis , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[4]  R. Ludwig,et al.  Drug Development in Pemphigoid Diseases , 2020, Acta dermato-venereologica.

[5]  S. Pasoto,et al.  Proposition of a novel animal model of systemic sclerosis induced by type V collagen in C57BL/6 mice that reproduces fibrosis, vasculopathy and autoimmunity , 2019, Arthritis Research & Therapy.

[6]  J. Fairley,et al.  The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid , 2019, Front. Immunol..

[7]  W. Sondermann,et al.  Dermatological complications of therapy with biologics in inflammatory autoimmune diseases , 2019, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[8]  T. Mayadas,et al.  Gene-diet interactions associated with complex trait variation in an advanced intercross outbred mouse line , 2019, Nature Communications.

[9]  E. Schmidt,et al.  Pemphigus , 2019, The Lancet.

[10]  C. Probst,et al.  Serological Diagnosis of Autoimmune Bullous Skin Diseases , 2019, Front. Immunol..

[11]  M. Seelen,et al.  Complement Activation in Autoimmune Bullous Dermatoses: A Comprehensive Review , 2019, Front. Immunol..

[12]  E. Papakonstantinou,et al.  Neurological disorders are associated with bullous pemphigoid , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  Y. Fujisawa,et al.  Possible involvement of IgE antibody in epidermolysis bullosa acquisita: detection and correlation , 2019, European Journal of Dermatology.

[14]  H. Shimizu,et al.  BP180 Autoantibodies Target Different Epitopes in Multiple Sclerosis or Alzheimer's Disease than in Bullous Pemphigoid. , 2019, The Journal of investigative dermatology.

[15]  S. Finzel,et al.  Skin inflammation associated with arthritis, synovitis and enthesitis. Part 2: rheumatoid arthritis, reactive arthritis, Reiter's syndrome, Lyme borreliosis, dermatomyositis and lupus erythematosus , 2019, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[16]  H. Busch,et al.  IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. , 2019, Journal of autoimmunity.

[17]  R. Eming,et al.  Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference , 2018, Front. Med..

[18]  D. Zillikens,et al.  Diagnosis of Autoimmune Blistering Diseases , 2018, Front. Med..

[19]  K. Kridin,et al.  The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations , 2018, Front. Med..

[20]  A. Sinha,et al.  The Evolving Story of Autoantibodies in Pemphigus Vulgaris: Development of the “Super Compensation Hypothesis” , 2018, Front. Med..

[21]  M. Schön,et al.  The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis , 2018, Front. Immunol..

[22]  R. Pollmann,et al.  TH1/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus. , 2018, The Journal of allergy and clinical immunology.

[23]  James J. Lee,et al.  Eosinophils Mediate Tissue Injury in the Autoimmune Skin Disease Bullous Pemphigoid. , 2017, The Journal of investigative dermatology.

[24]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[25]  J. Kaffenberger,et al.  The association between bullous pemphigoid and neurological disorders: a systematic review , 2017, European Journal of Dermatology.

[26]  James T. Elder,et al.  Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling , 2017, Human molecular genetics.

[27]  K. Papp,et al.  Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial , 2017, The Lancet.

[28]  A. Verkman,et al.  Mechanisms of Autoantibody-Induced Pathology , 2017, Front. Immunol..

[29]  L. Misery,et al.  First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial , 2017, The Lancet.

[30]  S. Ogston,et al.  HLA‐Cw6‐positive patients with psoriasis show improved response to methotrexate treatment , 2017, Clinical and experimental dermatology.

[31]  D. Zillikens,et al.  Reduced Skin Blistering in Experimental Epidermolysis Bullosa Acquisita After Anti-TNF Treatment , 2016, Molecular medicine.

[32]  H. Nakagawa,et al.  The first trial of CIM331, a humanized antihuman interleukin‐31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double‐blind, placebo‐controlled study , 2016, The British journal of dermatology.

[33]  E. R. Sutherland,et al.  Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial , 2016, The Lancet.

[34]  S. Krebs,et al.  Melanocyte antigen triggers autoimmunity in human psoriasis , 2015, The Journal of experimental medicine.

[35]  D. Zillikens,et al.  Caspase-1–Independent IL-1 Release Mediates Blister Formation in Autoantibody-Induced Tissue Injury through Modulation of Endothelial Adhesion Molecules , 2015, The Journal of Immunology.

[36]  B. Marinari,et al.  The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis , 2014, Nature Communications.

[37]  A. Christiano,et al.  Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition , 2014, Nature Medicine.

[38]  C. Rajkumar Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial , 2013 .

[39]  D. Zillikens,et al.  Pemphigoid diseases , 2013, The Lancet.

[40]  S. Ständer,et al.  [Chronic pruritus in autoimmune dermatoses : results of a comparative survey]. , 2012, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[41]  R. Valenta,et al.  The role of T‐cell reactivity towards the autoantigen α‐NAC in atopic dermatitis , 2011, The British journal of dermatology.

[42]  R. Ludwig,et al.  Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis? , 2009, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

[43]  C. Herzog,et al.  Psoriasis: a possible risk factor for development of coronary artery calcification , 2007, The British journal of dermatology.

[44]  Daniel B. Shin,et al.  Risk of myocardial infarction in patients with psoriasis. , 2006, JAMA.

[45]  L. Vaillant,et al.  A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. , 2002, The New England journal of medicine.

[46]  C Bona,et al.  Defining criteria for autoimmune diseases (Witebsky's postulates revisited) , 1993, Immunology today.

[47]  P. Calabresi,et al.  Occlusive vascular disease in psoriatic patients. , 1973, The New England journal of medicine.

[48]  J. Silverberg,et al.  Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus. , 2019, The Journal of allergy and clinical immunology.

[49]  L. Marshall,et al.  Pemphigus , 2017, Nature Reviews Disease Primers.